Table of Contents
Chemotherapy Research and Practice
Volume 2017 (2017), Article ID 8196434, 4 pages
https://doi.org/10.1155/2017/8196434
Clinical Study

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

1Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
2Centre for Cancer Epidemiology, ACTREC, Tata Memorial Centre, Mumbai, India
3Department of Pathology, Tata Memorial Hospital, Mumbai, India
4Department of Radiology, Tata Memorial Hospital, Mumbai, India
5Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, India

Correspondence should be addressed to Kumar Prabhash

Received 18 April 2017; Revised 6 September 2017; Accepted 26 September 2017; Published 23 October 2017

Academic Editor: Naoya Fujita

Copyright © 2017 Amit Joshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Amit Joshi, Vanita Noronha, Vijay M. Patil, et al., “Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?,” Chemotherapy Research and Practice, vol. 2017, Article ID 8196434, 4 pages, 2017. doi:10.1155/2017/8196434